Company news

Vcanbio Cell & Gene Engineering Corp., Ltd. Class A (SSE:600645) news

Vcanbio Cell & Gene Engineering Corp., Ltd. Class A news releases on 6ix. Latest, Sep 16, 2026: "Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement…

Vcanbio Cell & Gene Engineering Corp., Ltd. Class A (SSE:600645) news

Press releases & updates

"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Measures in the Form of Warning Letters Received by the Company and Relevant Persons

"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Performance Briefing

"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report

"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Progress in Wholly-owned Subsidiary's Clinical Trial for VUM02 Injection

"Vcanbio Cell & Gene Engineering Corp., Ltd"Announcement on Progress in Redemption of Temporarily Idle Raised Funds Used for Cash Management upon Expiration and Continuously Conducting Cash Management

Announcement on Convening the 2025 Annual Performance Briefing

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Return of Raised Funds Temporarily Used to Supplement Current Capital

Indicative Announcement on Convening the 2025 Annual General Meeting

Announcement on 2025 Annual Profit Distribution Plan

Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection

Announcement on Progress in Using Temporarily Idle Raised Funds for Cash Management

Announcement on Redemption of Idle Raised Funds Used for Cash Management upon Maturity

Announcement on Subsidiary’s Receipt of a Medical Device Registration Certificate

with the University of Chinese Academy of Sciences Education Foundation and the Progress in Hosting the Vcanbio Life Sciences Award

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025

Announcement on Canceling the Board of Supervisors and Amending the "Articles of Association"

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2025

Announcement on Wholly-owned Subsidiary Obtaining Notice of Approval for Drug Clinical Trials

Report for Q3 2025

Announcement on the Return of Idle Raised Funds for Cash Management to the Dedicated Fundraising Account

Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Report Performance Briefing

Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025

Announcement on Wholly-owned Subsidiary Obtaining Notice of Acceptance for Application of Drug Clinical Trials

Announcement on Resolutions of the 20th Extraordinary Meeting of the 11th Board of Directors

Announcement on Resolutions of the 19th Extraordinary Meeting of the 11th Board of Directors

Announcement on Extension of Pledge of Partial Equity of Persons Acting in Concert with Controlling Shareholders

Announcement on Returning Idle Raised Funds Used for Cash Management to Special Account for Raised Funds

Announcement on Wholly-owned Subsidiary Obtaining Notice of Acceptance of Application for Drug Clinical Trial

Announcement on Resolution of the 9th Extraordinary Meeting of the 11th Board of Supervisors

Announcement on Resolution of the 2024 Annual General Meeting

Announcement on Convening the 2024 Annual Performance Briefing

Announcement on Change of Accounting Policies

Announcement on Returning Idle Raised Funds Used for Temporarily Supplementing Current Capital

Announcement on the Resignation of Deputy General Manager and Secretary of the Board of Directors

Announcement on Returning Idle Raised Funds for Cash Management to Special Account for Raised Funds

Announcement on Signing Property Service Entrustment Contract and Related Transactions between Holding Subsidiaries and Tianjin Hongkan Property Operation Management Co., Ltd.

Announcement on Obtaining Notice of Acceptance for Drug Clinical Trial Application of the Wholly-owned Subsidiary

Announcement on Using Temporarily Idle Raised Funds and Self-owned Funds for Cash Management

Announcement on the Progress of Drug Clinical Trials and Orphan Drug Qualification Accreditation by FDA for a Wholly-owned Subsidiary

Announcement on Resolution of the 2nd Extraordinary General Meeting in 2024

Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2024

Notice on Convening the 2nd Extraordinary General Meeting in 2024

Announcement on Subsidiary's Signing of Supplementary Agreement to Commissioned R&D Service Contract

Announcement on Resolution of the 1st Extraordinary General Meeting in 2024

Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2024

Announcement on Resolutions of the 13th Interim Meeting of the 11th Board of Directors

Announcement on Change of Lead Financial Advisor for Continuous Supervision